SET and cancer: We next tested pharmacological modulation of SET by FTY720 (Fingolimod) [40], a FDA-approved immunosuppressive drug that has gained further attention as anti-cancer and PP2A activating drug, due to its ability to disrupt the binding between SET and PP2A [28, 41–43].